To determine Minimum Inhibitory Concentration (MIC) of Cefixime in Mahacef® Tablet 200mg and API Cefixime trihydrate compacted IP (API)
DOI:
https://doi.org/10.48165/20hmax39Keywords:
Minimum Inhibitory Concentration, Cefixime, Cefixime trihydrate compacted IP, Antibiotic resistanceAbstract
Antibiotic resistance is rising to dangerously high levels globally. New resistance mechanisms are emerging and spreading, thereby threatening our ability to treat common infectious diseases. In places where antibiotics can be bought for human or animal use without a prescription, the emergence and spread of resistance is made worse. This study endeavours to determine minimum inhibitory concentration (MIC) of Mahacef® 200mg Tablet and Cefixime Trihydrate API, both supplied by Mankind Pharma Limited. Methodology: Antibacterial activity of Cefixime on Salmonella enterica subsp. enterica serover Typhimurium was determined by Agar Dilution Method with Mueller Hinton Agar. Available strain of Salmonella enterica subsp. enterica serover Typhimurium (ATCC® 14028™) was used with Inoculum size was approximately 1000 cfu / plate. Dilutions were prepared in Phosphate buffer (pH 7.0, 0.1 mol/L) for Mahacef® 200 mg Tablet and Cefixime Trihydrate API, and used for the study. Results: Findings of this study demonstrate that both Mahacef® 200mg Tablet and Cefixime Trihydrate API have shown excellent antibacterial activity in vitro. MICs for the drug product as well as for the drug substance (API) are found to be 0.1 µg/mL against Salmonella enterica subsp. enterica serover Typhimurium. Conclusion: Mahacef® 200mg andCefixime Trihydrate API clearly establish support for its antimicrobial effectiveness and therefore, support values determined MIC for the viewpoint of medical fraternity that Cefixime is effective for management of typhoid fever.
References
1. Product Monograph of PrSUPRAX® (Cefixime tablets, Mfr. Std., 400 mg and Cefixime for oral suspension, Mfr. Std., 100 mg/5 mL), Sanofi-aventis Canada Inc., 2905 Place Louis-R.- Renaud, Laval, Quebec H7V 0A3. Submission Control No. 188553. Date of revision: 12 Jan 2016.
2. Barker AK, Brown K, Ahsan M, Sengupta S, Safdar N. Social determinants of antibiotic misuse: a qualitative study of community members in Haryana, India. BMC Public Health. 2017 Apr 19;17(1):333.
3. Barquist L, Langridge GC, Turner DJ, Phan MD, Turner AK, Bateman A, Parkhill J, Wain J, Gardner PP. A comparison of dense transposon insertion libraries in the Salmonella serovars Typhi and Typhimurium. Nucleic Acids Res. 2013 Apr;41(8):4549-64.
4. Yoon KB, Song BJ, Shin MY, Lim HC, Yoon YH, Jeon DY, Ha H, Yang SI, Kim JB. Antibiotic Resistance Patterns and Serotypes of Salmonella spp. Isolated at Jeollanam-do in Korea. Osong Public Health Res Perspect. 2017 Jun;8(3):211- 219.
5. Kowalska-Krochmal B, Dudek-Wicher R. The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance. Pathogens. 2021 Feb 4;10(2):165.
6. Performance Standards for Antimicrobial Susceptibility Testing; Clinical Laboratory Standards Institute®. M100, 30th Edition. January 2020 (Replaces M100, 29th ed.).
7. Clinical Pharmacology and Biopharmaceutics Review(s). Suprax® (Cefixime) 400 mg capsule. of Lupin Pharmaceuticals Inc. NDA No. 203195. Center for Drug Evaluation and Research. US FDA.
8. Matsumoto Y, Ikemoto A, Tawara S. Antibacterial activity of cefixime against Salmonella typhi and applicability of Etest. J
Infect Chemother. 1999 Sep;5(3):176-179.
9. Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man. Pediatr Infect Dis J. 1987 Oct;6(10):963-70.
